WO2012018881A3 - Methods and compositions for the regulation of rna - Google Patents

Methods and compositions for the regulation of rna Download PDF

Info

Publication number
WO2012018881A3
WO2012018881A3 PCT/US2011/046365 US2011046365W WO2012018881A3 WO 2012018881 A3 WO2012018881 A3 WO 2012018881A3 US 2011046365 W US2011046365 W US 2011046365W WO 2012018881 A3 WO2012018881 A3 WO 2012018881A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
rna
regulation
lncrna
Prior art date
Application number
PCT/US2011/046365
Other languages
French (fr)
Other versions
WO2012018881A2 (en
Inventor
Brian Bettencourt
Gregory Hinkle
Kenneth S. Koblan
Muthiah Manoharan
Stuart Pollard
Donna T. Ward
Original Assignee
Alnylam Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US37041410P priority Critical
Priority to US61/370,414 priority
Application filed by Alnylam Pharmaceuticals, Inc. filed Critical Alnylam Pharmaceuticals, Inc.
Publication of WO2012018881A2 publication Critical patent/WO2012018881A2/en
Publication of WO2012018881A3 publication Critical patent/WO2012018881A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/10Applications; Uses in screening processes
    • C12N2320/11Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Abstract

The invention relates to compositions and methods of modulating the status, activity or expression of long intervening non-coding RNA transcript (lncRNA) targets.
PCT/US2011/046365 2010-08-03 2011-08-03 Methods and compositions for the regulation of rna WO2012018881A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US37041410P true 2010-08-03 2010-08-03
US61/370,414 2010-08-03

Publications (2)

Publication Number Publication Date
WO2012018881A2 WO2012018881A2 (en) 2012-02-09
WO2012018881A3 true WO2012018881A3 (en) 2012-08-09

Family

ID=45560043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/046365 WO2012018881A2 (en) 2010-08-03 2011-08-03 Methods and compositions for the regulation of rna

Country Status (1)

Country Link
WO (1) WO2012018881A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US9328346B2 (en) 2010-11-12 2016-05-03 The General Hospital Corporation Polycomb-associated non-coding RNAs

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2013173598A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating atp2a2 expression
WO2013173652A1 (en) * 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
EP2850185A4 (en) 2012-05-16 2015-12-30 Rana Therapeutics Inc Compositions and methods for modulating utrn expression
JP2015518710A (en) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Compositions and methods for modulating the hemoglobin gene family expression
EP2850186B1 (en) 2012-05-16 2018-12-19 Translate Bio MA, Inc. Compositions and methods for modulating smn gene family expression
EP2943579B1 (en) * 2013-01-10 2018-09-12 Dharmacon, Inc. Libraries and methods for generating molecules
EP2813578A1 (en) * 2013-06-14 2014-12-17 Prestizia Methods for detecting an infectious agent, in particular HIV1, using long noncoding RNA
RU2016107434A (en) 2013-08-07 2017-09-15 Регенерон Фармасьютикалз, Инк. Non-human animals deficient dpnrnk
CN105705640B (en) * 2013-08-20 2019-02-15 非营利性组织佛兰芒综合大学生物技术研究所 Inhibit lncRNA for treating melanoma
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
EP3286310A4 (en) * 2015-04-24 2019-01-09 California Inst Of Techn Reactivation of x chromosome genes
CN105567804B (en) * 2015-12-07 2018-11-20 中山大学附属第医院 Nr_073415.2 cytomegalovirus infection detected in organ transplant patients and in the application kit
CN105567806B (en) * 2015-12-07 2018-11-20 中山大学附属第医院 Nr_027669.1 detecting fungal infections in organ transplant patients and a kit Application
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050064454A1 (en) * 2000-06-05 2005-03-24 Young Paul E. Cancer gene determination and therapeutic screening using signature gene sets
US20050153337A1 (en) * 2003-04-03 2005-07-14 Muthiah Manoharan iRNA conjugates
US20060134663A1 (en) * 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same
US20060240093A1 (en) * 2003-07-16 2006-10-26 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050064454A1 (en) * 2000-06-05 2005-03-24 Young Paul E. Cancer gene determination and therapeutic screening using signature gene sets
US20050153337A1 (en) * 2003-04-03 2005-07-14 Muthiah Manoharan iRNA conjugates
US20060240093A1 (en) * 2003-07-16 2006-10-26 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US20060134663A1 (en) * 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FORREST ET AL.: "Annotating non-coding transcription using functional genomics strategies.", BRIEF FUNCT. GENOMIC PROTEOMIC, vol. 8, no. 6, 2009, pages 437 - 443 *
GUPTA ET AL.: "Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.", NATURE, vol. 464, no. 7291, 15 April 2010 (2010-04-15), pages 1071 - 1076, XP055037476, DOI: doi:10.1038/nature08975 *
KHALIL ET AL.: "Many human large intergenic noncoding RNAs associate with chromatin- modifying complexes and affect gene expression.", PROC. NATL. ACAD. SCI., vol. 106, no. 28, 2009, pages 11667 - 11672, XP055073351, DOI: doi:10.1073/pnas.0904715106 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328346B2 (en) 2010-11-12 2016-05-03 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression

Also Published As

Publication number Publication date
WO2012018881A2 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
AU2011325956B2 (en) Polycomb-associated non-coding RNAs
MX2012000510A (en) Bace inhibitors.
WO2010146463A3 (en) Composition comprising rebaudioside d for reducing or eliminating aftertaste and preparation method thereof
WO2011090760A4 (en) Heteroaryl compounds and uses thereof
MX2010004674A (en) Alpha-amylase variants with altered properties.
WO2013016168A3 (en) Systems and methods of storing data
WO2011133875A3 (en) Metalloenzyme inhibitor compounds
WO2012061290A3 (en) Pesticidal compositions and processes related thereto
RS55163B1 (en) Stabilized fibronectin domain compositions, methods and uses
EP2281039A4 (en) Systems, methods and compositions for optical stimulation of target cells
WO2010089411A3 (en) Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2012003405A4 (en) Sgc stimulators
PT2898075E (en) Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
WO2015071474A3 (en) Crispr-cas system materials and methods
EA028067B1 (en) Methods of controlling or preventing bleeding or bleeding events
GB201218752D0 (en) Mineral complex, compositions thereof, and methods of using the same
WO2012061607A3 (en) Compositions comprising functionalized carbon-based nanostructures and related methods
MX349630B (en) Alpha-amylases.
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
WO2013052913A4 (en) Methods and processes for non-invasive assessment of genetic variations
WO2011031489A3 (en) Umbilical cord amniotic membrane products
CA2798622A1 (en) Indoles
TW201028092A (en) Use of dithiine-tetracarboximides for controlling phytopathogenic fungi
WO2012166425A3 (en) Methods of amplifying whole genome of a single cell
IN2012DN03883A (en) "heterocyclic compounds useful as pdk1 inhibitors"

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815240

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11815240

Country of ref document: EP

Kind code of ref document: A2